Answers are grounded in this paper and cite their sources.
Lung cancer screening (LCS) with low-dose CT (LDCT) imaging of the chest consistently has demonstrated mortality benefit in large randomized trials. Annual LDCT imaging for lung screening has been recommended in the United States for a decade and is covered by public and private insurance plans. Nonetheless, advocates and practitioners of LCS now are grappling with parallel problems of poor uptake and poor adherence. These are equally important problems: studies demonstrating a mortality benefit for LCS with LDCT imaging showed nearly perfect adherence, so we cannot expect the benefits of LCS to extend to poorly adherent screening participants.
No takes yet. Share an insight, caveat, or question.
Nathani et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: